ERBB2 and breast carcinoma: Taken together, treatment with a single i.v. dose of HER2-TTC at 250 or 500 kBq/kg resulted in marked inhibition of intratibial tumor growth and associated tumor-induced abnormal bone formation in the HER2-positive BT-474 mouse model mimicking breast cancer with bone metastases.